BK-5Cl-NM-AMT, or βk-5Cl-NM-αMT, also known as β-keto-5-chloro-N-methyl-αMT or α,N-dimethyl-5-chloro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.

It is known to induce the release of serotonin and dopamine, with respective EC₅₀Tooltip half-maximal effective concentration values of 200 nM and 865 nM in rat brain synaptosomes, whereas norepinephrine release was not reported. In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT₁, 5-HT₂, and 5-HT₃ receptors. In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI).

BK-5Cl-NM-AMT was first described in the literature by 2023. It was patented by Matthew Baggott and Tactogen as a potential novel entactogen. BK-5Cl-NM-AMT is the 5-chloro derivative of BK-NM-AMT. Other analogues of the drug include BK-5F-NM-AMT and BK-5Br-NM-AMT.